Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology

Selected Publications


A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors.

Journal Article Mol Cancer Ther · April 8, 2024 A majority of cancer patients receive radiation therapy as part of their treatment regimens whether using external beam therapy or locally-delivered radioisotopes. While often effective, some tumors are inadequately controlled with radiation and radiation ... Full text Link to item Cite

Sublethal engagement of apoptotic pathways in residual cancer.

Journal Article Trends Cell Biol · March 2024 Cytotoxic chemo-, radio-, and targeted therapies frequently elicit apoptotic cancer cell death. Mitochondrial outer membrane permeabilization (MOMP) is a critical, regulated step in this apoptotic pathway. The residual cancer cells that survive treatment s ... Full text Link to item Cite

Drug dependence in cancer is exploitable by optimally constructed treatment holidays.

Journal Article Nat Ecol Evol · January 2024 Cancers with acquired resistance to targeted therapy can become simultaneously dependent on the presence of the targeted therapy drug for survival, suggesting that intermittent therapy may slow resistance. However, relatively little is known about which tu ... Full text Link to item Cite

CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.

Journal Article Mol Cancer Res · November 1, 2023 UNLABELLED: PIK3CA is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%-25% of gastric cancers display activating PIK3CA mutations, including 80% of Epstein-Ba ... Full text Link to item Cite

Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating &l ... Full text Cite

Table S8 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Antibody dilutions for primary and secondary antibodies used</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Figure S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719</p> ... Full text Cite

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibit ... Full text Cite

Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating &l ... Full text Cite

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors.

Journal Article Mol Cancer Ther · April 8, 2024 A majority of cancer patients receive radiation therapy as part of their treatment regimens whether using external beam therapy or locally-delivered radioisotopes. While often effective, some tumors are inadequately controlled with radiation and radiation ... Full text Link to item Cite

Sublethal engagement of apoptotic pathways in residual cancer.

Journal Article Trends Cell Biol · March 2024 Cytotoxic chemo-, radio-, and targeted therapies frequently elicit apoptotic cancer cell death. Mitochondrial outer membrane permeabilization (MOMP) is a critical, regulated step in this apoptotic pathway. The residual cancer cells that survive treatment s ... Full text Link to item Cite

Drug dependence in cancer is exploitable by optimally constructed treatment holidays.

Journal Article Nat Ecol Evol · January 2024 Cancers with acquired resistance to targeted therapy can become simultaneously dependent on the presence of the targeted therapy drug for survival, suggesting that intermittent therapy may slow resistance. However, relatively little is known about which tu ... Full text Link to item Cite

CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.

Journal Article Mol Cancer Res · November 1, 2023 UNLABELLED: PIK3CA is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%-25% of gastric cancers display activating PIK3CA mutations, including 80% of Epstein-Ba ... Full text Link to item Cite

Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating &l ... Full text Cite

Table S8 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Antibody dilutions for primary and secondary antibodies used</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Figure S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719</p> ... Full text Cite

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibit ... Full text Cite

Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating &l ... Full text Cite

Table S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Z-transformed difference scores for each cell line as calculated from beta scores</p> ... Full text Cite

Table S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Sequences of guide RNAs used to generate genetic knockouts</p> ... Full text Cite

Table S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Beta scores generated for DMSO and BYL719 treated populations using MAGeCK analysis pipeline</p> ... Full text Cite

Table S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Sequences of guide RNAs used to generate genetic knockouts</p> ... Full text Cite

Table S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Z-transformed difference scores for each cell line as calculated from beta scores</p> ... Full text Cite

Table S8 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Antibody dilutions for primary and secondary antibodies used</p> ... Full text Cite

Figure S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719</p> ... Full text Cite

Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibit ... Full text Cite

Figure S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S4 shows loss of BCL-XL and BYL719 treatment in additional gastric cancer cell line</p> ... Full text Cite

Figure S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S4 shows loss of BCL-XL and BYL719 treatment in additional gastric cancer cell line</p> ... Full text Cite

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline</p> ... Full text Cite

Figure S2 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen</p> ... Full text Cite

Figure S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S6 shows down-regulation of RUNX1 in BYL719 resistant cells</p> ... Full text Cite

Figure S2 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen</p> ... Full text Cite

Figure S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Figure S6 shows down-regulation of RUNX1 in BYL719 resistant cells</p> ... Full text Cite

Table S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · November 1, 2023 <p>Beta scores generated for DMSO and BYL719 treated populations using MAGeCK analysis pipeline</p> ... Full text Cite

Integrative PTEN Enhancer Discovery Reveals a New Model of Enhancer Organization.

Journal Article bioRxiv · September 21, 2023 Enhancers possess both structural elements mediating promoter looping and functional elements mediating gene expression. Traditional models of enhancer-mediated gene regulation imply genomic overlap or immediate adjacency of these elements. We test this mo ... Full text Link to item Cite

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13.

Journal Article Proc Natl Acad Sci U S A · September 19, 2023 Evidence has long suggested that epidermal growth factor receptor (EGFR) may play a prominent role in triple-negative breast cancer (TNBC) pathogenesis, but clinical trials of EGFR inhibitors have yielded disappointing results. Using a candidate drug scree ... Full text Link to item Cite

Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibit ... Full text Cite

Figure S2 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen</p> ... Full text Cite

Table S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Z-transformed difference scores for each cell line as calculated from beta scores</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Table S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Sequences of guide RNAs used to generate genetic knockouts</p> ... Full text Cite

Figure S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S6 shows down-regulation of RUNX1 in BYL719 resistant cells</p> ... Full text Cite

Figure S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S4 shows loss of BCL-XL and BYL719 treatment in additional gastric cancer cell line</p> ... Full text Cite

Table S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Z-transformed difference scores for each cell line as calculated from beta scores</p> ... Full text Cite

Figure S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S6 shows down-regulation of RUNX1 in BYL719 resistant cells</p> ... Full text Cite

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline</p> ... Full text Cite

Table S8 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Antibody dilutions for primary and secondary antibodies used</p> ... Full text Cite

Figure S5 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719</p> ... Full text Cite

Figure S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719</p> ... Full text Cite

Table S6 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Sequences of guide RNAs used to generate genetic knockouts</p> ... Full text Cite

Figure S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Table S8 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Antibody dilutions for primary and secondary antibodies used</p> ... Full text Cite

Table S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Beta scores generated for DMSO and BYL719 treated populations using MAGeCK analysis pipeline</p> ... Full text Cite

Figure S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719</p> ... Full text Cite

Figure S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S4 shows loss of BCL-XL and BYL719 treatment in additional gastric cancer cell line</p> ... Full text Cite

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline</p> ... Full text Cite

Table S3 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Beta scores generated for DMSO and BYL719 treated populations using MAGeCK analysis pipeline</p> ... Full text Cite

Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <div>Abstract<p><i>PIK3CA</i> is the second most mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased translation, proliferation, and survival. Some 4%–25% of gastric cancers display activating &l ... Full text Cite

Figure S2 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen</p> ... Full text Cite

Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Other · August 9, 2023 <p>S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibit ... Full text Cite

ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1.

Journal Article Proc Natl Acad Sci U S A · April 18, 2023 The hypoxia-inducible factor 1-α (HIF-1α) enables cells to adapt and respond to hypoxia (Hx), and the activity of this transcription factor is regulated by several oncogenic signals and cellular stressors. While the pathways controlling normoxic degradatio ... Full text Open Access Link to item Cite

Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis.

Journal Article Nature communications · March 2023 During apoptosis, mitochondrial outer membrane permeabilization (MOMP) enables certain mitochondrial matrix macromolecules to escape into the cytosol. However, the fate of mitochondrial RNA (mtRNA) during apoptosis is unknown. Here, we demonstrate that MOM ... Full text Cite

Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.

Journal Article Trends Cancer · February 2023 The intrinsic apoptosis pathway is controlled by the BCL-2 family of proteins. Although the pro-survival members of this family can help cancer cells evade apoptosis, they may also produce apoptotic vulnerabilities that can potentially be exploited therape ... Full text Link to item Cite

MCB-613 exploits a collateral sensitivity in drug resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1.

Journal Article bioRxiv · January 19, 2023 Targeted therapies have revolutionized cancer chemotherapy. Unfortunately, most patients develop multifocal resistance to these drugs within a matter of months. Here, we used a high-throughput phenotypic small molecule screen to identify MCB-613 as a compo ... Full text Link to item Cite

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.

Journal Article Cancer research · January 2023 Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic restorati ... Full text Cite

Challenges and Emerging Opportunities for Targeting mTOR in Cancer.

Journal Article Cancer Res · November 2, 2022 The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, ... Full text Link to item Cite

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.

Journal Article NPJ Precis Oncol · October 23, 2022 Intrahepatic cholangiocarcinoma (ICC) remains a deadly malignancy lacking systemic therapies for advanced disease. Recent advancements include selective FGFR1-3 inhibitors for the 15% of ICC patients harboring fusions, although survival is limited by poor ... Full text Link to item Cite

Cancer genes disfavoring T cell immunity identified via integrated systems approach.

Journal Article Cell Rep · August 2, 2022 Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these therapies for more patients. To this end, we use a three-step approach to identi ... Full text Link to item Cite

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

Journal Article Nat Cancer · July 2022 Selinexor is a first-in-class inhibitor of the nuclear exportin XPO1 that was recently approved by the US Food and Drug Administration for the treatment of multiple myeloma and diffuse large B-cell lymphoma. In relapsed/refractory acute myeloid leukemia (A ... Full text Link to item Cite

Drivers of intrinsic resistance.

Journal Article Nat Chem Biol · June 2022 Precision oncology requires an understanding of the genes and pathways that dictate therapeutic response. Through specialized analysis of drug sensitivity patterns across hundreds of genomically annotated cancer cell lines, specific and actionable drivers ... Full text Link to item Cite

A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models.

Journal Article The Journal of clinical investigation · June 2022 Wnt signaling regulates the balance between stemness and differentiation in multiple tissues and in cancer. RNF43-mutant pancreatic cancers are dependent on Wnt production, and pharmacologic blockade of the pathway, e.g., by PORCN inhibitors, leads to tumo ... Full text Cite

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.

Journal Article Mol Cancer Ther · May 4, 2022 Human papilloma virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with an unmet need for more effective, less toxic treatments. Currently, both the disease and the treatment of HNSCC cause significant mortality ... Full text Link to item Cite

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.

Journal Article Sci Transl Med · March 30, 2022 Residual cancer cells that survive drug treatments with targeted therapies act as a reservoir from which eventual resistant disease emerges. Although there is great interest in therapeutically targeting residual cells, efforts are hampered by our limited k ... Full text Link to item Cite

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.

Conference Mol Cancer Ther · January 2022 Oncogenic RAS signaling is an attractive target for fusion-negative rhabdomyosarcoma (FN-RMS). Our study validates the role of the ERK MAPK effector pathway in mediating RAS dependency in a panel of H/NRASQ61X mutant RMS cells and correlates in vivo effica ... Full text Link to item Cite

A high throughput proliferation and cytotoxicity assay for co-cultured isogenic cell lines.

Journal Article MethodsX · 2022 PTEN is a well-known tumor suppressor that is inactivated or suppressed at a high frequency in cancer. We sought an assay to screen compounds for ones that differentially inhibited proliferation or induced cytotoxicity in PTEN mutated cancer cells. We empl ... Full text Link to item Cite

ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.

Journal Article Cell reports · October 2021 Targeting mitochondrial metabolism has emerged as a treatment option for cancer patients. The ABL tyrosine kinases promote metastasis, and enhanced ABL signaling is associated with a poor prognosis in lung adenocarcinoma patients. Here we show that ABL kin ... Full text Cite

Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.

Journal Article Sci Adv · September 17, 2021 Single-cell analysis tools have made substantial advances in characterizing genomic heterogeneity; however, tools for measuring phenotypic heterogeneity have lagged due to the increased difficulty of handling live biology. Here, we report a single-cell phe ... Full text Open Access Link to item Cite

Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.

Journal Article NPJ Breast Cancer · July 2, 2021 Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we h ... Full text Link to item Cite

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

Journal Article Cancer Discov · December 2020 Deciphering the impact of metabolic intervention on response to anticancer therapy may elucidate a path toward improved clinical responses. Here, we identify amino acid-related pathways connected to the folate cycle whose activation predicts sensitivity to ... Full text Link to item Cite

Abstract 6406: FAK and MEK co-targeting: A new multimodal precision therapy for GNAQ-driven uveal melanoma

Conference Cancer Research · August 15, 2020 AbstractUveal melanoma (UM) is characterized by gain-of-function mutations in GNAQ or GNA11, encoding Gα proteins from the Gq/11 family. UM is the most common eye malignancy in adults. Approximately 50% of U ... Full text Cite

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.

Journal Article Cell Rep · June 16, 2020 We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR genetic screens identify combinations causing apoptotic anti-tumor activity. The most pot ... Full text Link to item Cite

Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.

Journal Article Nat Genet · April 2020 Local adaptation directs populations towards environment-specific fitness maxima through acquisition of positively selected traits. However, rapid environmental changes can identify hidden fitness trade-offs that turn adaptation into maladaptation, resulti ... Full text Link to item Cite

Druggable Vulnerabilities in Therapy-Resistant Lung Cancers

Conference JOURNAL OF THORACIC ONCOLOGY · February 1, 2020 Link to item Cite

Overcoming MCL-1-driven adaptive resistance to targeted therapies.

Journal Article Nat Commun · January 27, 2020 Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with n ... Full text Link to item Cite

Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis.

Journal Article J Biol Chem · January 3, 2020 Aerobic glycolysis or the Warburg effect (WE) is characterized by increased glucose uptake and incomplete oxidation to lactate. Although the WE is ubiquitous, its biological role remains controversial, and whether glucose metabolism is functionally differe ... Full text Link to item Cite

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Conference Blood · November 13, 2019 Metabolic rewiring of neoplastic cells engenders metabolic liabilities that can be exploited to design innovative therapeutic strategies, including those to increase the therapeutic index of existing anticancer therapies. We hypothesized that metab ... Full text Cite

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Conference Blood · November 13, 2019 Background: Acute myeloid leukemia (AML) is an aggressive myeloid cancer of the hematopoietic system that primarily affects older adults and is characterized by therapy resistance and dismal outcomes. Novel approaches to t ... Full text Cite

PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.

Journal Article Oncogene · October 2019 Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is aggressive and lethal. Although there is an urgent need for effective therapeutics in treating pancreatic cancer, none of the targeted therapies tested in clinical trials to date significantly i ... Full text Link to item Cite

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.

Journal Article Sci Adv · September 2019 Extrinsic pathway agonists have failed repeatedly in the clinic for three core reasons: Inefficient ligand-induced receptor multimerization, poor pharmacokinetic properties, and tumor intrinsic resistance. Here, we address these factors by (i) using a high ... Full text Link to item Cite

Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer

Conference Cancer Research · July 1, 2019 AbstractPancreatic ductal adenocarcinoma (PDAC) patients have a dismal five-year survival rate of just eight percent in the advanced metastatic setting. Outcomes with standard chemotherapy regimens are less ... Full text Cite

Label propagation defines signaling networks associated with recurrently mutated cancer genes.

Journal Article Sci Rep · June 28, 2019 Human tumors have distinct profiles of genomic alterations, and each of these alterations has the potential to cause unique changes to cellular homeostasis. Detailed analyses of these changes could reveal downstream effects of genomic alterations, contribu ... Full text Link to item Cite

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.

Journal Article Cell Metab · May 7, 2019 Crosstalk between metabolic and survival pathways is critical for cellular homeostasis, but the connectivity between these processes remains poorly defined. We used loss-of-function CRISPR/Cas9 knockout screening to identify metabolic genes capable of infl ... Full text Link to item Cite

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Journal Article PLoS One · 2019 BACKGROUND: Radium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized tha ... Full text Link to item Cite

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.

Journal Article Nat Commun · October 15, 2018 Intrinsic resistance to anti-HER2 therapy in breast cancer remains an obstacle in the clinic, limiting its efficacy. However, the biological basis for intrinsic resistance is poorly understood. Here we performed a CRISPR/Cas9-mediated loss-of-function gene ... Full text Open Access Link to item Cite

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.

Journal Article Nat Commun · August 29, 2018 While inhibitors of BCL-2 family proteins (BH3 mimetics) have shown promise as anti-cancer agents, the various dependencies or co-dependencies of diverse cancers on BCL-2 genes remain poorly understood. Here we develop a drug screening approach to define t ... Full text Link to item Cite

An acoustofluidic trap and transfer approach for organizing a high density single cell array.

Journal Article Lab Chip · July 10, 2018 We demonstrate a hybrid microfluidic system that combines fluidic trapping and acoustic switching to organize an array of single cells at high density. The fluidic trapping step is achieved by balancing the hydrodynamic resistances of three parallel channe ... Full text Open Access Link to item Cite

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.

Journal Article Trends Cancer · May 2018 Oncogenic KRAS can activate numerous effector pathways to drive malignant progression. However, the relationships between specific effectors and oncogenic phenotypes, and the extent to which these relationships vary across heterogeneous tumors, are incompl ... Full text Link to item Cite

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.

Journal Article Nat Commun · April 26, 2018 Altered mitochondrial dynamics can broadly impact tumor cell physiology. Using genetic and pharmacological profiling of cancer cell lines and human tumors, we here establish that perturbations to the mitochondrial dynamics network also result in specific t ... Full text Link to item Cite

Bayesian Approximate Kernel Regression with Variable Selection.

Journal Article J Am Stat Assoc · 2018 Nonlinear kernel regression models are often used in statistics and machine learning because they are more accurate than linear models. Variable selection for kernel regression models is a challenge partly because, unlike the linear regression setting, the ... Full text Link to item Cite

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Journal Article Cell Rep · December 5, 2017 Diverse pathways drive resistance to BRAF/MEK inhibitors in BRAF-mutant melanoma, suggesting that durable control of resistance will be a challenge. By combining statistical modeling of genomic data from matched pre-treatment and post-relapse patient tumor ... Full text Link to item Cite

Abstract PR18: Leveraging synthetic lethality to target convergent therapeutic resistance

Conference Molecular Cancer Therapeutics · October 1, 2017 AbstractOur laboratory uses genomic and pharmacological methods to define the pathways of resistance to targeted anticancer therapies. Toward this end, we recently developed a technique in which engineered l ... Full text Cite

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Journal Article Cell Rep · July 25, 2017 Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematical ... Full text Link to item Cite

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.

Journal Article Nat Commun · June 8, 2017 KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal cancer (CRC). Through genetic screens, we unexpectedly find that mutant HRAS, which is rarely found in CRC, is a stronger driver of resistance than mutant KRAS. ... Full text Link to item Cite

Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection.

Journal Article Elife · April 20, 2017 Latent Epstein-Barr virus (EBV) infection is causally linked to several human cancers. EBV expresses viral oncogenes that promote cell growth and inhibit the apoptotic response to uncontrolled proliferation. The EBV oncoprotein LMP1 constitutively activate ... Full text Open Access Link to item Cite

Suppressing oncogenic transcription with a little healthy competition.

Journal Article Sci Transl Med · January 25, 2017 Therapeutic strategies that stabilize wild-type MLL proteins have selective activity in MLL-rearranged leukemias. ... Full text Link to item Cite

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Journal Article Sci Transl Med · December 14, 2016 Therapies that efficiently induce apoptosis are likely to be required for durable clinical responses in patients with solid tumors. Using a pharmacological screening approach, we discovered that combined inhibition of B cell lymphoma-extra large (BCL-XL) a ... Full text Open Access Link to item Cite

An EXITS strategy for decreasing cancer risk in women.

Journal Article Sci Transl Med · December 7, 2016 Full text Link to item Cite

Hacking T cells with synthetic circuits to program antitumor responses

Journal Article Science Translational Medicine · October 26, 2016 Full text Cite

Two faces of circulating breast cancer cells

Journal Article Science Translational Medicine · September 14, 2016 Full text Cite

Mapping a path for precision cancer therapies

Journal Article Science Translational Medicine · July 20, 2016 Full text Cite

Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes.

Journal Article Genes Cancer · July 2016 Functional genomics approaches such as gain- and loss-of-function screening can efficiently reveal genes that control cancer cell growth, survival, signal transduction, and drug resistance, but distilling the results of large-scale screens into actionable ... Full text Open Access Link to item Cite

Targeting the cancer cells that just won't go away

Journal Article Science Translational Medicine · June 22, 2016 Full text Cite

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

Journal Article Sci Rep · June 10, 2016 ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to investiga ... Full text Link to item Cite

An Automated High-throughput Array Microscope for Cancer Cell Mechanics.

Journal Article Sci Rep · June 6, 2016 Changes in cellular mechanical properties correlate with the progression of metastatic cancer along the epithelial-to-mesenchymal transition (EMT). Few high-throughput methodologies exist that measure cell compliance, which can be used to understand the im ... Full text Link to item Cite

Collaborating tumor cells overcome multitargeted antiangiogenic therapies

Journal Article Science Translational Medicine · May 11, 2016 Full text Cite

ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.

Journal Article Cell Rep · April 12, 2016 Imaging studies in animals and in humans have indicated that the oxygenation and nutritional status of solid tumors is dynamic. Furthermore, the extremely low level of glucose within tumors, while reflecting its rapid uptake and metabolism, also suggests t ... Full text Link to item Cite

Intercepting reversible drug tolerance to improve targeted therapy

Journal Article Science Translational Medicine · March 30, 2016 Full text Cite

Cooperative nutrient accumulation sustains growth of mammalian cells.

Journal Article Sci Rep · December 1, 2015 The coordination of metabolic processes to allow increased nutrient uptake and utilization for macromolecular synthesis is central for cell growth. Although studies of bulk cell populations have revealed important metabolic and signaling requirements that ... Full text Link to item Cite

Mapping the Pathways of Resistance to Targeted Therapies.

Journal Article Cancer Res · October 15, 2015 Resistance substantially limits the depth and duration of clinical responses to targeted anticancer therapies. Through the use of complementary experimental approaches, investigators have revealed that cancer cells can achieve resistance through adaptation ... Full text Link to item Cite

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

Journal Article Nat Commun · September 22, 2015 Molecular targeted drugs are clinically effective anti-cancer therapies. However, tumours treated with single agents usually develop resistance. Here we use colorectal cancer (CRC) as a model to study how the acquisition of resistance to EGFR-targeted ther ... Full text Link to item Cite

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation.

Journal Article J Clin Invest · January 2015 Activation of CD4+ T cells results in rapid proliferation and differentiation into effector and regulatory subsets. CD4+ effector T cell (Teff) (Th1 and Th17) and Treg subsets are metabolically distinct, yet the specific metabolic differences that modify T ... Full text Open Access Link to item Cite

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Journal Article Sci Signal · December 23, 2014 Cancer cells can activate diverse signaling pathways to evade the cytotoxic action of drugs. We created and screened a library of barcoded pathway-activating mutant complementary DNAs to identify those that enhanced the survival of cancer cells in the pres ... Full text Link to item Cite

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Journal Article Sci Signal · December 23, 2014 Myeloproliferative neoplasms (MPNs) frequently have an activating mutation in the gene encoding Janus kinase 2 (JAK2). Thus, targeting the pathway mediated by JAK and its downstream substrate, signal transducer and activator of transcription (STAT), may yi ... Full text Link to item Cite

Science signaling podcast: 23 December 2014

Journal Article Science Signaling · December 23, 2014 This Podcast features an interview with Kris Wood, senior author of two Research Articles that appear in the 23 December 2014 issue of Science Signaling, about signaling pathways that enable cancer cells to develop drug resistance. Myeloprolfierative neopl ... Full text Cite

Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells.

Journal Article Cell Rep · March 27, 2014 Drug resistance in bacterial infections and cancers constitutes a major threat to human health. Treatments often include several interacting drugs, but even potent therapies can become ineffective in resistant mutants. Here, we simplify the picture of drug ... Full text Link to item Cite

MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.

Journal Article Sci Signal · May 15, 2012 Cell microarrays are a promising tool for performing large-scale functional genomic screening in mammalian cells at reasonable cost, but owing to technical limitations they have been restricted for use with a narrow range of cell lines and short-term assay ... Full text Link to item Cite

Growth signaling at the nexus of stem cell life and death.

Journal Article Cell Stem Cell · September 4, 2009 Stress can activate tumor-suppressive mechanisms, causing the loss of adult stem cell function with age. In this issue of Cell Stem Cell and in Nature, Castilho et al. (2009) and Harrison et al. (2009) highlight the importance of mTOR signaling in stem cel ... Full text Link to item Cite

Electroactive controlled release thin films.

Journal Article Proc Natl Acad Sci U S A · February 19, 2008 We present the fabrication of nanoscale electroactive thin films that can be engineered to undergo remotely controlled dissolution in the presence of a small applied voltage (+1.25 V) to release precise quantities of chemical agents. These films, which are ... Full text Link to item Cite

Tumor-targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide.

Journal Article Bioconjug Chem · February 2008 Before gene therapy can be used in clinical settings, safe and efficient DNA delivery systems must be developed to overcome a range of extra- and intracellular transport barriers. As a step toward the development of a modular, multifunctional gene delivery ... Full text Link to item Cite

Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films

Journal Article Proceedings of the National Academy of Sciences of the United States of America · July 4, 2006 We present the fabrication of conformal, hydrolytically degradable thin films capable of administering sustained, multiagent release profiles. Films are constructed one molecular layer at a time by using the layer-by-layer, directed-deposition technique; t ... Full text Cite

Tunable drug release from hydrolytically degradable layer-by-layer thin films

Journal Article Langmuir · February 15, 2005 The development of new thin film fabrication techniques that allow for precise control of degradation and drug release properties could represent an important advance in the fields of drug delivery and biomedicine. Polyelectrolyte layer-by-layer (LBL) thin ... Full text Cite

Degradation of chlorinated organics by membrane-immobilized nanosized metals

Journal Article Environmental Progress · October 1, 2004 The use of electronegative metals, such as Fe, has been extensively studied for the treatment of ground-water containing toxic chlorinated organics. Much of the recent work has been focused on the use of nanoscale particles with diameters from 2 to 100 nm. ... Full text Cite